The ads that get the most attention tend to be either those that are most dramatically distributed, with seemingly every single email address getting multiple copies… or those that come with a big promise and a very high price. Today’s topic of interest is the latter, since we’re told that Stansberry Venture Value’s Dave Lashmet believes this stock has the most valuable pill in development anywhere in the world… and they’re selling their nonrefundable letter for $5,000.
There is some wiggle room in that “nonrefundable”, in that they will give you Stansberry credit if the stock doesn’t double… and the initial subscription goes for 18 months instead of the typical year, but it looks like they’re trying to hold the line on that $5,000 sales price instead of offering it “on sale,” as they more typically do with these high cost letters. And after those 18 months, it renews at $5,500 every year.
So that’s out of reach for a lot of individual investors, of course — you’d have to have a sizable portfolio allocation to higher-risk speculative and “venture” investments to justify spending that much money to get advice on that sector… but, naturally, many Gumshoe readers are curious: What the heck stock he’s talking about?
Time to put the Thinkolator on the case… starting with a bit of overview:
“In short, our team believes a tiny biotech company most people have never heard of will soon announce positive trial data for an experimental treatment, which tens of millions of Americans desperately need.
“Based on developments over the past several weeks, we expect the announcement will lead to nationwide approval of the company’s treatment, and will make their patents among the most valuable in the entire pharmaceutical universe.”
And these are the clues that I’ve seen in the various email ads…
“… the treatment Dave has uncovered – currently in Phase III trials – may soon help prevent the #1 cause of death in the United States.
“A disease that currently accounts for one out of every four deaths in our country.”
OK, so that’s “heart disease” for the win in that category. And apparently this company is releasing clinical trial results sometime soon…
"reveal" emails? If not,
just click here...
“As soon as next month, new data from this treatment’s ongoing trial could cement a new era of hope for the tens of millions of Americans who can potentially benefit from this treatment. And for investors, it could mean a windfall…
“That’s because this particular treatment in development is one of the most lucrative types of medicine in the of biotech world.”
And they back that up by citing a few big annual sales numbers from some others of “this type” of medicine, including $6.5 billion for AstraZeneca and $12.9 billion for Pfizer… which means we’re talking about statins and/or cholesterol drugs (those numbers are sales totals from Lipitor and Crestor in past years).
What other clues do we get? Here are a couple:
“… today, the company we recommend you invest in right now has a market capitalization of only $1 billion….
“… most drugs in this class have the negative side effect of causing muscular weakness. As a result, 40% of folks who are prescribed this type of drug don’t stay on them for very long.
“But with the radical new pill Dave has discovered, those side effects could be totally removed for the first time ever.”
And there are some catalysts coming up very soon, which is where they get the “get in before next month’s announcement” urgency…
“… we now know this little-known firm will announce the first of two remaining pivotal Phase 3 results next month.
“If the results are positive, as we expect, you want to be invested in the company BEFORE that announcement….
“As Dave wrote in his email to me, “Two phase III trials are complete. If the other two are successful, this stock is a Grand Slam.””
To be fair, they are also clear in the ad about the possibility that those two trials might NOT be successful… which gives us the fairly typical, “don’t buy a drug developer unless you can afford to lose all your money if you’re wrong” kind of language… they say if the best happens, everyone celebrates and they file for FDA approval early next year and the stock could double in a couple months… if the worst happens and both trial results are disappointing, it might go to zero.
And that is indeed important to remember — for folks who aren’t used to biotech stocks, particularly pre-commercial companies who might only have one or two drugs in development, it is eminently possible for the market to turn on one piece of news and tell you that the company you thought was worth $1 billion is now worth 90% less. It’s all about guessing the future, predicting the clinical trial results and, later, trying to figure out how much of it they can sell, and at what price… which is hard all the way around, and one reason why I rarely delve into this space personally.
But, caveats aside, what’s the stock? I tossed all those clues into the Mighty, Mighty Thinkolator, and we get an answer that will sound familiar for many of you: Esperion Therapeutics (ESPR).
Esperion calls itself “the lipid management company” and has added the “beyond statins” tagline to some of their marketing materials has had a couple huge moves over the past 3+ years as it tries to move its Bempedoic Acid through clinical trials to get FDA approval to market it both as a way to lower some types of cholesterol and as acardiovascular disease “risk reduction” solution… both of which would obviously be huge markets if the drug is approved and insurers and doctors endorse it as a drug that should have widespread use in the huge “at risk” population for heart disease.
And yes, they do have two Phase III clinical trials that are still underway, and which will release data over the next two months — one in August and one in September.
I won’t try to parse the clinical trial results, since that’s not my bailiwick at all, but it seems that a substantial amount of the volatility in recent years has been relate to the expected safety profile — how many of the patients had bad stuff happen to them on Bempedoic Acid, compared to placebo, and my recollection is that some bad news on that front back in 2015 or 2016 led to real weakness in the stock. It’s clearly still front of mind for the company, since the first part of their analyst day presentation last week was entirely focused on safety.
Which makes sense — a drug that might be prescribed to tens of millions of people who are not in imminent danger or sick has a far higher safety hurdle to leap than a cancer drug that’s going to be prescribed to a much smaller number of people who are very likely to die in six months.
So those fluctuating opinions about the effectiveness and the safety of this drug have clearly given the stock price the jitters — it went from $15 to almost $120, then back down to $10 from 2014-2016, and then things started to look up a bit and the stock gradually climbed back into the $80s over the past couple years… until a higher mortality rate in one of their trial results in early May cut the stock in half in a matter of hours.
Which means that yes, sure, the stock could easily move dramatically over the next couple months as these last two important Phase III trials are reported. And that I have no personal guess as to whether that’s going to be a move up or down, though it’s probably good that the stock reset back in May has served to lower expectations a little bit.
And with that, dear friends, I’ll leave it to you to make your own decisions — it’s a stock that was covered by Dr. KSS many times back when he was writing biotech columns for us, and it certainly gets a lot of biotech pundit attention because of that huge potential market, but I suppose it should go without saying that I don’t know whether or not Dave Lashmet is right in predicting a double over the next year and a half (or the next month or two).
I know there are many of you that are far wiser biotech investors than I am… so what do you think? Have you been following Esperion? Have any thoughts on the drug or the company? Expecting big things in the months to come? Let us know with a comment below.